Connection

Allen Kaplan to Humans

This is a "connection" page, showing publications Allen Kaplan has written about Humans.
Connection Strength

1.774
  1. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023 02; 78(2):389-401.
    View in: PubMed
    Score: 0.032
  2. Bradykinin formation by mutant plasminogen. Blood. 2022 05 05; 139(18):2732-2733.
    View in: PubMed
    Score: 0.031
  3. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. J Allergy Clin Immunol Pract. 2022 03; 10(3):716-722.
    View in: PubMed
    Score: 0.030
  4. Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema. Clin Rev Allergy Immunol. 2021 Jun; 60(3):348-356.
    View in: PubMed
    Score: 0.029
  5. The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. J Allergy Clin Immunol Pract. 2021 06; 9(6):2195-2208.
    View in: PubMed
    Score: 0.029
  6. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J Allergy Clin Immunol Pract. 2021 03; 9(3):1067-1078.
    View in: PubMed
    Score: 0.028
  7. Hereditary angioedema: Investigational therapies and future research. Allergy Asthma Proc. 2020 11 01; 41(Suppl 1):S51-S54.
    View in: PubMed
    Score: 0.028
  8. Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin Immunol. 2021 Feb; 147(2):507-509.
    View in: PubMed
    Score: 0.028
  9. Diagnosis and treatment of chronic spontaneous urticaria. Allergy. 2020 07; 75(7):1830-1832.
    View in: PubMed
    Score: 0.026
  10. Preventing anaphylaxis fatalities: Should we target bradykinin? J Allergy Clin Immunol. 2020 05; 145(5):1365-1366.
    View in: PubMed
    Score: 0.026
  11. C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema. J Allergy Clin Immunol Pract. 2020 03; 8(3):892-900.
    View in: PubMed
    Score: 0.026
  12. Treatment of urticaria: a clinical and mechanistic approach. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):387-392.
    View in: PubMed
    Score: 0.025
  13. Basophil histamine release in patients with chronic spontaneous urticaria: Optimize or minimize. J Allergy Clin Immunol. 2019 08; 144(2):622-623.
    View in: PubMed
    Score: 0.025
  14. Chronic Spontaneous Urticaria: The Devil's Itch. J Allergy Clin Immunol Pract. 2018 Jul - Aug; 6(4):1097-1106.
    View in: PubMed
    Score: 0.024
  15. Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria. Allergy Asthma Proc. 2018 May 01; 39(3):184-190.
    View in: PubMed
    Score: 0.023
  16. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
    View in: PubMed
    Score: 0.022
  17. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. Immunol Allergy Clin North Am. 2017 08; 37(3):513-525.
    View in: PubMed
    Score: 0.022
  18. Reply. J Allergy Clin Immunol. 2017 05; 139(5):1720-1721.
    View in: PubMed
    Score: 0.022
  19. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr; 72(4):519-533.
    View in: PubMed
    Score: 0.021
  20. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. J Allergy Clin Immunol. 2017 Jul; 140(1):170-176.
    View in: PubMed
    Score: 0.021
  21. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent. Clin Rev Allergy Immunol. 2016 Oct; 51(2):207-15.
    View in: PubMed
    Score: 0.021
  22. Fibrinolysis and bradykinin formation: From in?vitro observations to human disease in "just" 45?years. J Allergy Clin Immunol. 2016 11; 138(5):1424-1425.
    View in: PubMed
    Score: 0.021
  23. Vibratory Urticaria and ADGRE2. N Engl J Med. 2016 07 07; 375(1):94-5.
    View in: PubMed
    Score: 0.021
  24. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016 Feb; 137(2):474-81.
    View in: PubMed
    Score: 0.020
  25. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. 2016 06; 137(6):1822-1829.e1.
    View in: PubMed
    Score: 0.019
  26. How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria. J Allergy Clin Immunol Pract. 2015 Jul-Aug; 3(4):648.
    View in: PubMed
    Score: 0.019
  27. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014 Nov-Dec; 35(6):444-53.
    View in: PubMed
    Score: 0.018
  28. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes. Allergy. 2015 Jan; 70(1):115-9.
    View in: PubMed
    Score: 0.018
  29. Biologic agents and the therapy of chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2014 Aug; 14(4):347-53.
    View in: PubMed
    Score: 0.018
  30. Bradykinin-mediated diseases. Chem Immunol Allergy. 2014; 100:140-7.
    View in: PubMed
    Score: 0.018
  31. The bradykinin-forming cascade: a historical perspective. Chem Immunol Allergy. 2014; 100:205-13.
    View in: PubMed
    Score: 0.018
  32. Therapy of chronic urticaria: a simple, modern approach. Ann Allergy Asthma Immunol. 2014 May; 112(5):419-25.
    View in: PubMed
    Score: 0.018
  33. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014; 121:41-89.
    View in: PubMed
    Score: 0.017
  34. The maddening itch: an approach to chronic urticaria. J Investig Allergol Clin Immunol. 2014; 24(1):1-5.
    View in: PubMed
    Score: 0.017
  35. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul; 132(1):101-9.
    View in: PubMed
    Score: 0.017
  36. In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. J Renin Angiotensin Aldosterone Syst. 2015 Jun; 16(2):321-7.
    View in: PubMed
    Score: 0.017
  37. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol. 2013 Aug; 132(2):470-5.
    View in: PubMed
    Score: 0.017
  38. Biologic agents in the treatment of urticaria. Curr Allergy Asthma Rep. 2012 Aug; 12(4):288-91.
    View in: PubMed
    Score: 0.016
  39. What to do with refractory urticaria patients. Curr Allergy Asthma Rep. 2011 Jun; 11(3):189-91.
    View in: PubMed
    Score: 0.014
  40. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol. 2011 May; 127(5):1300-2.
    View in: PubMed
    Score: 0.014
  41. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010 Nov; 126(5):918-25.
    View in: PubMed
    Score: 0.014
  42. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010 Aug; 47(13):2161-9.
    View in: PubMed
    Score: 0.014
  43. Kinins, airway obstruction, and anaphylaxis. Chem Immunol Allergy. 2010; 95:67-84.
    View in: PubMed
    Score: 0.013
  44. Kinin formation in C1 inhibitor deficiency. J Allergy Clin Immunol. 2010 Jun; 125(6):1411-2; author reply 1412.
    View in: PubMed
    Score: 0.013
  45. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010 Mar; 104(3):193-204.
    View in: PubMed
    Score: 0.013
  46. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol. 2010 Jan; 104(1):50-4.
    View in: PubMed
    Score: 0.013
  47. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol. 2009 Jul; 124(1):143-9.
    View in: PubMed
    Score: 0.012
  48. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009 Mar; 123(3):713-7.
    View in: PubMed
    Score: 0.012
  49. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008 Sep; 122(3):569-73.
    View in: PubMed
    Score: 0.012
  50. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol. 2008 Sep; 101(3):279-86.
    View in: PubMed
    Score: 0.012
  51. Chronic urticaria: what is new, where are we headed. Allergol Immunopathol (Madr). 2007 Mar-Apr; 35(2):57-61.
    View in: PubMed
    Score: 0.011
  52. Angioedema. J Am Acad Dermatol. 2005 Sep; 53(3):373-88; quiz 389-92.
    View in: PubMed
    Score: 0.010
  53. Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005 Jul; 289(1):H251-7.
    View in: PubMed
    Score: 0.010
  54. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005 Jun; 94(6):662-9.
    View in: PubMed
    Score: 0.010
  55. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy. 2005 May; 35(5):554-9.
    View in: PubMed
    Score: 0.009
  56. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol. 2005 Apr; 115(4):815-21.
    View in: PubMed
    Score: 0.009
  57. A new mechanism for immunologic initiation of asthma. Proc Natl Acad Sci U S A. 2005 Feb 01; 102(5):1267-8.
    View in: PubMed
    Score: 0.009
  58. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol. 2005; 86:159-208.
    View in: PubMed
    Score: 0.009
  59. Comments regarding 'Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells' by Asero et al. A.P. Kaplan. Clin Exp Allergy. 2004 Nov; 34(11):1803; author reply 1804-5.
    View in: PubMed
    Score: 0.009
  60. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004 Sep; 114(3):465-74; quiz 475.
    View in: PubMed
    Score: 0.009
  61. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost. 2004 Jan; 91(1):61-70.
    View in: PubMed
    Score: 0.009
  62. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb Haemost. 2003 Nov; 90(5):787-95.
    View in: PubMed
    Score: 0.009
  63. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J Thromb Haemost. 2003 Nov; 1(11):2444-9.
    View in: PubMed
    Score: 0.009
  64. IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera. Allergy. 2003 Aug; 58(8):802-7.
    View in: PubMed
    Score: 0.008
  65. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol. 2003 Jul; 112(1):218.
    View in: PubMed
    Score: 0.008
  66. Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. Int Immunopharmacol. 2002 Dec; 2(13-14):1851-9.
    View in: PubMed
    Score: 0.008
  67. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. Int Immunopharmacol. 2002 Dec; 2(13-14):1875-85.
    View in: PubMed
    Score: 0.008
  68. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002 Apr; 109(4):694-700.
    View in: PubMed
    Score: 0.008
  69. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 07; 77(7):1961-1990.
    View in: PubMed
    Score: 0.008
  70. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002 Jan 17; 346(3):175-9.
    View in: PubMed
    Score: 0.008
  71. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):896-900.
    View in: PubMed
    Score: 0.008
  72. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol. 2002 Jan; 109(1):114-8.
    View in: PubMed
    Score: 0.008
  73. Immediate pressure urticaria. Allergy. 2002 Jan; 57(1):56-7.
    View in: PubMed
    Score: 0.008
  74. SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems. Front Immunol. 2021; 12:767347.
    View in: PubMed
    Score: 0.007
  75. The international EAACI/GA?LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 03; 77(3):734-766.
    View in: PubMed
    Score: 0.007
  76. gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema. Inflammation. 2022 Feb; 45(1):116-128.
    View in: PubMed
    Score: 0.007
  77. Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Mol Immunol. 2021 08; 136:150-160.
    View in: PubMed
    Score: 0.007
  78. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema. J Allergy Clin Immunol Pract. 2021 06; 9(6):2284-2292.
    View in: PubMed
    Score: 0.007
  79. Chemokines, chemokine receptors and allergy. Int Arch Allergy Immunol. 2001 Apr; 124(4):423-31.
    View in: PubMed
    Score: 0.007
  80. Activation of the kinin-forming cascade on the surface of endothelial cells. Biol Chem. 2001 Jan; 382(1):71-5.
    View in: PubMed
    Score: 0.007
  81. Activation of the plasma kinin forming cascade along cell surfaces. Int Arch Allergy Immunol. 2001 Jan-Mar; 124(1-3):339-42.
    View in: PubMed
    Score: 0.007
  82. C1 inhibitor deficiency: hereditary and acquired forms. J Investig Allergol Clin Immunol. 2001; 11(4):211-9.
    View in: PubMed
    Score: 0.007
  83. Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy. 2020 08; 75(8):2115-2123.
    View in: PubMed
    Score: 0.007
  84. Protease activity in single-chain prekallikrein. Blood. 2020 02 20; 135(8):558-567.
    View in: PubMed
    Score: 0.007
  85. sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. Mol Immunol. 2020 03; 119:27-34.
    View in: PubMed
    Score: 0.007
  86. Diagnostic tests for urticaria and angioedema. Clin Allergy Immunol. 2000; 15:111-26.
    View in: PubMed
    Score: 0.007
  87. Pathogenesis and treatment of chronic urticaria. Postgrad Med. 1999 Dec; 106(7 Suppl):12-7.
    View in: PubMed
    Score: 0.007
  88. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol. 1999 Sep; 92(3):246-55.
    View in: PubMed
    Score: 0.006
  89. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacology. 1999 Sep; 43(2-3):203-10.
    View in: PubMed
    Score: 0.006
  90. Nomenclature of factor XI and the contact system. J Thromb Haemost. 2019 12; 17(12):2216-2219.
    View in: PubMed
    Score: 0.006
  91. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med. 1999 Aug; 5(8):555-63.
    View in: PubMed
    Score: 0.006
  92. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol. 1999 Jul; 104(1):169-72.
    View in: PubMed
    Score: 0.006
  93. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol. 1999 Jan; 90(1):89-99.
    View in: PubMed
    Score: 0.006
  94. An IgE-dependent histamine-releasing factor (HRF) identical to a previously described human protein (P23) Allergy. 1998 Jul; 53(7):631-2.
    View in: PubMed
    Score: 0.006
  95. Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol. 1998 May; 101(5):672-6.
    View in: PubMed
    Score: 0.006
  96. Effect of neurotropin on the binding of high molecular weight kininogen and Hageman factor to human umbilical vein endothelial cells and the autoactivation of bound Hageman factor. Biochem Pharmacol. 1998 Apr 15; 55(8):1175-80.
    View in: PubMed
    Score: 0.006
  97. Chemokines and the late-phase reaction. Allergy. 1998; 53(45 Suppl):27-32.
    View in: PubMed
    Score: 0.006
  98. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018 03; 141(3):1138-1139.e7.
    View in: PubMed
    Score: 0.006
  99. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
    View in: PubMed
    Score: 0.006
  100. Binding of activation of kinin-forming proteins on vascular endothelial cells. Immunopharmacology. 1997 Jun; 36(2-3):201-7.
    View in: PubMed
    Score: 0.005
  101. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol. 1997 Apr; 99(4):461-5.
    View in: PubMed
    Score: 0.005
  102. Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria. Ann Allergy Asthma Immunol. 2017 04; 118(4):524.
    View in: PubMed
    Score: 0.005
  103. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol. 1997; 66:225-72.
    View in: PubMed
    Score: 0.005
  104. The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunol Rev. 2016 11; 274(1):281-289.
    View in: PubMed
    Score: 0.005
  105. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8552-7.
    View in: PubMed
    Score: 0.005
  106. Further characterization of histamine releasing chemokines present in fractionated supernatants derived from human mononuclear cells. Clin Exp Allergy. 1996 Aug; 26(8):926-33.
    View in: PubMed
    Score: 0.005
  107. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016 10; 117(4):370-377.e1.
    View in: PubMed
    Score: 0.005
  108. Bradykinin levels during experimental nasal infection with rhinovirus and attenuated influenza virus. Immunopharmacology. 1996 Jun; 33(1-3):311-3.
    View in: PubMed
    Score: 0.005
  109. Interactions of factor XII with platelets and endothelial cells. Immunopharmacology. 1996 May; 32(1-3):24-7.
    View in: PubMed
    Score: 0.005
  110. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol. 1996 Jan; 97(1 Pt 1):104-12.
    View in: PubMed
    Score: 0.005
  111. Relationship of histamine-releasing factors and histamine-releasing inhibitory factors to chemokine group of cytokine. Allergy Asthma Proc. 1996 Jan-Feb; 17(1):5-11.
    View in: PubMed
    Score: 0.005
  112. Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. J Allergy Clin Immunol Pract. 2016 Mar-Apr; 4(2):352-3.
    View in: PubMed
    Score: 0.005
  113. Chemokines and the allergic response. Exp Dermatol. 1995 Aug; 4(4 Pt 2):260-5.
    View in: PubMed
    Score: 0.005
  114. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. J Allergy Clin Immunol Pract. 2015 Sep-Oct; 3(5):743-50.e1.
    View in: PubMed
    Score: 0.005
  115. Assembly of the human plasma kinin-forming cascade along the surface of vascular endothelial cells. Int Arch Allergy Immunol. 1995 May-Jun; 107(1-3):93-4.
    View in: PubMed
    Score: 0.005
  116. Chemokines of the alpha, beta-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. J Allergy Clin Immunol. 1995 Feb; 95(2):574-86.
    View in: PubMed
    Score: 0.005
  117. Chemokines as allergic mediators--relationship to histamine-releasing factors. Allergy. 1994 Aug; 49(7):495-501.
    View in: PubMed
    Score: 0.004
  118. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 May; 69(5):602-16.
    View in: PubMed
    Score: 0.004
  119. Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23-24 August 2012. Inflamm Res. 2014 Mar; 63(3):173-8.
    View in: PubMed
    Score: 0.004
  120. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem. 1993 Jun 05; 268(16):11982-7.
    View in: PubMed
    Score: 0.004
  121. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol. 1993 Mar 01; 150(5):1932-43.
    View in: PubMed
    Score: 0.004
  122. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood. 1993 Mar 01; 81(5):1306-11.
    View in: PubMed
    Score: 0.004
  123. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
    View in: PubMed
    Score: 0.004
  124. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013; 8(2):e53773.
    View in: PubMed
    Score: 0.004
  125. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012 Nov-Dec; 33 Suppl 1:S145-56.
    View in: PubMed
    Score: 0.004
  126. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol. 1992 Jul 15; 149(2):636-42.
    View in: PubMed
    Score: 0.004
  127. Effect of Neurotropin on the activation of the plasma kallikrein-kinin system. Biochem Pharmacol. 1992 Mar 17; 43(6):1361-9.
    View in: PubMed
    Score: 0.004
  128. Connective tissue-activating peptide-III and its derivative, neutrophil-activating peptide-2, release histamine from human basophils. J Allergy Clin Immunol. 1992 Mar; 89(3):666-72.
    View in: PubMed
    Score: 0.004
  129. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med. 1992 Feb 01; 175(2):489-93.
    View in: PubMed
    Score: 0.004
  130. Cytokine stimulation of human basophil histamine release. Immunol Ser. 1992; 57:573-86.
    View in: PubMed
    Score: 0.004
  131. Studies of the activation and inhibition of the plasma kallikrein-kinin system. Agents Actions Suppl. 1992; 38 ( Pt 3):317-28.
    View in: PubMed
    Score: 0.004
  132. IL-8 inhibits histamine release from human basophils induced by histamine-releasing factors, connective tissue activating peptide III, and IL-3. J Immunol. 1991 Sep 15; 147(6):1920-4.
    View in: PubMed
    Score: 0.004
  133. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
    View in: PubMed
    Score: 0.004
  134. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):506-16.
    View in: PubMed
    Score: 0.004
  135. Histamine releasing factors. Clin Exp Allergy. 1991 Jan; 21 Suppl 1:8-16.
    View in: PubMed
    Score: 0.004
  136. Histamine-releasing factors. Int Arch Allergy Appl Immunol. 1991; 94(1-4):148-53.
    View in: PubMed
    Score: 0.004
  137. Histamine releasing factors and cytokine-dependent activation of basophils and mast cells. Adv Immunol. 1991; 50:237-60.
    View in: PubMed
    Score: 0.004
  138. Unmet clinical needs in chronic spontaneous urticaria. A GA?LEN task force report. Allergy. 2011 Mar; 66(3):317-30.
    View in: PubMed
    Score: 0.003
  139. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010 Oct; 12(10):765-75.
    View in: PubMed
    Score: 0.003
  140. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010 Aug; 105(2):142-8.
    View in: PubMed
    Score: 0.003
  141. Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin. Mol Cell Neurosci. 2010 Nov; 45(3):226-33.
    View in: PubMed
    Score: 0.003
  142. Relationship of one form of human histamine-releasing factor to connective tissue activating peptide-III. J Clin Invest. 1990 May; 85(5):1516-21.
    View in: PubMed
    Score: 0.003
  143. Urticaria: the relationship of duration of lesion to pathogenesis. Allergy Proc. 1990 Jan-Feb; 11(1):15-8.
    View in: PubMed
    Score: 0.003
  144. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity. Blood. 1989 Aug 01; 74(2):695-702.
    View in: PubMed
    Score: 0.003
  145. Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme. Inflammation. 1989 Jun; 13(3):295-308.
    View in: PubMed
    Score: 0.003
  146. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009 Jun; 39(6):777-87.
    View in: PubMed
    Score: 0.003
  147. Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. J Immunol Methods. 1989 Apr 21; 119(1):19-25.
    View in: PubMed
    Score: 0.003
  148. Purification and further characterization of human mononuclear cell histamine-releasing factor. J Clin Invest. 1989 Apr; 83(4):1204-10.
    View in: PubMed
    Score: 0.003
  149. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem Pharmacol. 1989 Mar 15; 38(6):993-1000.
    View in: PubMed
    Score: 0.003
  150. Studies of the cleavage of human high molecular weight kininogen by purified plasma and tissue kallikreins, and upon contact activation of plasma. Adv Exp Med Biol. 1989; 247B:317-24.
    View in: PubMed
    Score: 0.003
  151. Relationship of Hageman factor activation to the formation of bradykinin in humans: a historical perspective. Prog Clin Biol Res. 1989; 297:311-23.
    View in: PubMed
    Score: 0.003
  152. Pathways of kinin formation and role in allergic diseases. Clin Immunol Immunopathol. 1989 Jan; 50(1 Pt 2):S41-51.
    View in: PubMed
    Score: 0.003
  153. Responsiveness to human mononuclear cell-derived histamine-releasing factor. Studies of allergic status and the role of IgE. J Immunol. 1988 Oct 15; 141(8):2688-92.
    View in: PubMed
    Score: 0.003
  154. Recombinant human interleukin-1 beta causes histamine release from human basophils. J Allergy Clin Immunol. 1988 Aug; 82(2):218-23.
    View in: PubMed
    Score: 0.003
  155. Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity. Arthritis Rheum. 1988 Aug; 31(8):1000-6.
    View in: PubMed
    Score: 0.003
  156. Human recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3 cause basophil histamine release. J Clin Invest. 1988 Jul; 82(1):17-20.
    View in: PubMed
    Score: 0.003
  157. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood. 1988 May; 71(5):1334-40.
    View in: PubMed
    Score: 0.003
  158. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol. 1988 Feb; 90(2):213-7.
    View in: PubMed
    Score: 0.003
  159. Mediators of inflammation: an overview. Methods Enzymol. 1988; 163:3-23.
    View in: PubMed
    Score: 0.003
  160. Human Hageman factor and its fragments. Methods Enzymol. 1988; 163:68-80.
    View in: PubMed
    Score: 0.003
  161. Prekallikrein. Methods Enzymol. 1988; 163:85-95.
    View in: PubMed
    Score: 0.003
  162. Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol. 1988; 6:49-83.
    View in: PubMed
    Score: 0.003
  163. Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin. J Immunol. 1987 Oct 15; 139(8):2744-8.
    View in: PubMed
    Score: 0.003
  164. The coagulation-kinin pathway of human plasma. Blood. 1987 Jul; 70(1):1-15.
    View in: PubMed
    Score: 0.003
  165. Basophil secretion in chronic urticaria: autoantibody-dependent or not? J Allergy Clin Immunol. 2007 Sep; 120(3):729-30.
    View in: PubMed
    Score: 0.003
  166. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor. J Biol Chem. 1986 Nov 15; 261(32):14965-8.
    View in: PubMed
    Score: 0.003
  167. Surfactant protein A and D in human sinus mucosa: a preliminary report. ORL J Otorhinolaryngol Relat Spec. 2007; 69(1):57-60.
    View in: PubMed
    Score: 0.003
  168. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol. 1986 Nov; 78(5 Pt 1):914-8.
    View in: PubMed
    Score: 0.003
  169. Pleural fluid and peripheral eosinophilia from hemothorax: hypothesis of the pathogenesis of EPE in hemothorax and pneumothorax. Am J Med Sci. 2006 Sep; 332(3):148-52.
    View in: PubMed
    Score: 0.003
  170. Characterization and functional studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine. Arthritis Rheum. 1986 Aug; 29(8):944-55.
    View in: PubMed
    Score: 0.003
  171. The effect of C1 inhibitor upon Hageman factor autoactivation. Blood. 1986 Jul; 68(1):239-43.
    View in: PubMed
    Score: 0.003
  172. The intrinsic coagulation/kinin pathway--the classical complement pathway and their interactions. Adv Exp Med Biol. 1986; 198 Pt B:11-25.
    View in: PubMed
    Score: 0.002
  173. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood. 1985 Sep; 66(3):636-41.
    View in: PubMed
    Score: 0.002
  174. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem. 1985 Apr 10; 260(7):4257-63.
    View in: PubMed
    Score: 0.002
  175. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy. 2005 Apr; 35(4):456-60.
    View in: PubMed
    Score: 0.002
  176. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005 Mar; 115(3):584-91.
    View in: PubMed
    Score: 0.002
  177. Assessment of histamine release and kinin formation in man: identification of kinin degradation products and characterization of a lymphocyte-dependent histamine releasing factor. Int Arch Allergy Appl Immunol. 1985; 77(1-2):64-8.
    View in: PubMed
    Score: 0.002
  178. Alterations in eotaxin, monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 after systemic steroid treatment for nasal polyps. Otolaryngol Head Neck Surg. 2004 Nov; 131(5):585-9.
    View in: PubMed
    Score: 0.002
  179. Drug-induced skin disease. J Allergy Clin Immunol. 1984 Oct; 74(4 Pt 2):573-9.
    View in: PubMed
    Score: 0.002
  180. World Allergy Organization guidelines for prevention of allergy and allergic asthma. Int Arch Allergy Immunol. 2004 Sep; 135(1):83-92.
    View in: PubMed
    Score: 0.002
  181. Eucalyptus as a specific irritant causing vocal cord dysfunction. Ann Allergy Asthma Immunol. 2004 Sep; 93(3):299-303.
    View in: PubMed
    Score: 0.002
  182. Studies of complement autoactivatability in hereditary angioedema: direct relationship to functional C-1-INA and the effect of classical pathway activators. Clin Immunol Immunopathol. 1984 Jul; 32(1):101-10.
    View in: PubMed
    Score: 0.002
  183. Exercise-induced hives. J Allergy Clin Immunol. 1984 May; 73(5 Pt 2):704-7.
    View in: PubMed
    Score: 0.002
  184. Immunoreactive tissue kallikrein in human serum. J Lab Clin Med. 1984 May; 103(5):731-8.
    View in: PubMed
    Score: 0.002
  185. Unusual cold-induced disorders: cold-dependent dermatographism and systemic cold urticaria. J Allergy Clin Immunol. 1984 Apr; 73(4):453-6.
    View in: PubMed
    Score: 0.002
  186. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation. Fed Proc. 1983 Nov; 42(14):3123-7.
    View in: PubMed
    Score: 0.002
  187. Chronic urticaria. Possible causes, suggested treatment alternatives. Postgrad Med. 1983 Sep; 74(3):209-15, 218-22.
    View in: PubMed
    Score: 0.002
  188. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol. 1983 Jul; 72(1):54-60.
    View in: PubMed
    Score: 0.002
  189. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest. 1983 May; 71(5):1450-6.
    View in: PubMed
    Score: 0.002
  190. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol. 1983 Feb; 71(2):177-83.
    View in: PubMed
    Score: 0.002
  191. Mechanisms of bradykinin generation in human plasma. Monogr Allergy. 1983; 18:272-6.
    View in: PubMed
    Score: 0.002
  192. Initiation of contact activation of human plasma. Adv Exp Med Biol. 1983; 156:45-61.
    View in: PubMed
    Score: 0.002
  193. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood. 1982 Jul; 60(1):64-70.
    View in: PubMed
    Score: 0.002
  194. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem. 1982 Feb 25; 257(4):1779-84.
    View in: PubMed
    Score: 0.002
  195. Interaction of the clotting, kinin-forming, complement, and fibrinolytic pathways in inflammation. Ann N Y Acad Sci. 1982; 389:25-38.
    View in: PubMed
    Score: 0.002
  196. Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. J Allergy Clin Immunol. 1981 Dec; 68(6):438-41.
    View in: PubMed
    Score: 0.002
  197. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med. 1981 Oct 29; 305(18):1074-7.
    View in: PubMed
    Score: 0.002
  198. Exercise-induced anaphylaxis as a manifestation of cholinergic urticaria. J Allergy Clin Immunol. 1981 Oct; 68(4):319-24.
    View in: PubMed
    Score: 0.002
  199. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships. Crit Rev Immunol. 1981 Sep; 3(1):75-93.
    View in: PubMed
    Score: 0.002
  200. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 2001 Sep; 108(3):394-401.
    View in: PubMed
    Score: 0.002
  201. Histamine release and therapy of severe dermatographism. J Allergy Clin Immunol. 1981 Aug; 68(2):103-5.
    View in: PubMed
    Score: 0.002
  202. The pathogenic basis of urticaria and angioedema: recent advances. Am J Med. 1981 Apr; 70(4):755-8.
    View in: PubMed
    Score: 0.002
  203. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981 Mar 01; 153(3):665-76.
    View in: PubMed
    Score: 0.002
  204. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res. 1980 Oct 15; 20(2):173-89.
    View in: PubMed
    Score: 0.002
  205. The physical urticarias. Int J Dermatol. 1980 Oct; 19(8):417-35.
    View in: PubMed
    Score: 0.002
  206. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem. 1980 Aug 10; 255(15):7281-6.
    View in: PubMed
    Score: 0.002
  207. The role of cyproheptadine in the treatment of cold urticaria. J Allergy Clin Immunol. 1980 Apr; 65(4):309-12.
    View in: PubMed
    Score: 0.002
  208. Autoactivatability of human Hageman factor (factor XII). Biochem Biophys Res Commun. 1980 Feb 12; 92(3):803-10.
    View in: PubMed
    Score: 0.002
  209. Plasmin can activate plasma prorenin but is not required for the alkaline phase of acid activation. Clin Sci (Lond). 1979 Dec; 57 Suppl 5:97s-99s.
    View in: PubMed
    Score: 0.002
  210. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999 Nov; 104(5):1071-8.
    View in: PubMed
    Score: 0.002
  211. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc Natl Acad Sci U S A. 1979 Nov; 76(11):5914-8.
    View in: PubMed
    Score: 0.002
  212. Hageman-factor-dependent fibrinolysis: generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood. 1979 Oct; 54(4):850-62.
    View in: PubMed
    Score: 0.002
  213. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci U S A. 1979 Oct; 76(10):4862-6.
    View in: PubMed
    Score: 0.002
  214. Contrast agents and anaphylactic-like reactions. J Allergy Clin Immunol. 1979 Apr; 63(4):225-7.
    View in: PubMed
    Score: 0.002
  215. Evaluation of a patient with cold and cholinergic urticaria. J Allergy Clin Immunol. 1979 Jan; 63(1):35-8.
    View in: PubMed
    Score: 0.002
  216. The role of high molecular weight kininogen in contact activation of coagulation, fibrinolysis and kinin generation. Adv Exp Med Biol. 1979; 120B:71-91.
    View in: PubMed
    Score: 0.002
  217. Structure-function correlation of human kininogen. Monogr Allergy. 1979; 14:212-7.
    View in: PubMed
    Score: 0.002
  218. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 1978 Jun; 61(6):350-4.
    View in: PubMed
    Score: 0.001
  219. Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen. J Exp Med. 1978 Feb 01; 147(2):488-99.
    View in: PubMed
    Score: 0.001
  220. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol. 1998; 16(4):403-29.
    View in: PubMed
    Score: 0.001
  221. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest. 1977 Dec; 60(6):1376-80.
    View in: PubMed
    Score: 0.001
  222. Mediators of urticaria and angioedema. J Allergy Clin Immunol. 1977 Nov; 60(5):324-32.
    View in: PubMed
    Score: 0.001
  223. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. J Biol Chem. 1977 Sep 10; 252(17):6097-104.
    View in: PubMed
    Score: 0.001
  224. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest. 1977 Jul; 60(1):18-31.
    View in: PubMed
    Score: 0.001
  225. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy. 1997 Jun; 27(6):653-63.
    View in: PubMed
    Score: 0.001
  226. The role of Hageman factor, prekallifrein, and high molecular weight kininogen in the generation of bradykinin and the initiation of coagulation and fibrinolysis. Monogr Allergy. 1977; 12:120-30.
    View in: PubMed
    Score: 0.001
  227. Mediator release from basophil granulocytes in chronic myelogenous leukemia. J Allergy Clin Immunol. 1976 Dec; 58(6):623-34.
    View in: PubMed
    Score: 0.001
  228. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976 Nov; 73(11):4179-83.
    View in: PubMed
    Score: 0.001
  229. Human C1q induces eosinophil migration. Clin Immunol Immunopathol. 1996 Oct; 81(1):48-54.
    View in: PubMed
    Score: 0.001
  230. The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin-generation. Semin Thromb Hemost. 1976 Jul; 3(1):1-26.
    View in: PubMed
    Score: 0.001
  231. Pattern of nasal secretions during experimental influenza virus infection. Rhinology. 1996 Mar; 34(1):2-8.
    View in: PubMed
    Score: 0.001
  232. Activation and control mechanisms of Hageman factor-dependent pathways of coagulation, fibrinolysis, and kinin generation and their contribution to the inflammatory response. J Allergy Clin Immunol. 1975 Dec; 56(6):491-506.
    View in: PubMed
    Score: 0.001
  233. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest. 1975 Dec; 56(6):1650-62.
    View in: PubMed
    Score: 0.001
  234. Effects of PBMC-derived histamine-releasing factors on histamine release from human skin and lung mast cells. Clin Exp Allergy. 1995 Sep; 25(9):890-5.
    View in: PubMed
    Score: 0.001
  235. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol. 1975 Jun; 55(6):394-402.
    View in: PubMed
    Score: 0.001
  236. Mononuclear cell chemotactic activity of kallikrein and plasminogen activator and its inhibition by C1 inhibitor and alpha 2-macroglobulin. J Immunol. 1974 Dec; 113(6):1928-34.
    View in: PubMed
    Score: 0.001
  237. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin. J Exp Med. 1974 Dec 01; 140(6):1615-30.
    View in: PubMed
    Score: 0.001
  238. Activation of human Hageman factor (factor XII) in the presence of zinc and phosphate ions. Braz J Med Biol Res. 1994 Aug; 27(8):1817-28.
    View in: PubMed
    Score: 0.001
  239. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest. 1974 Feb; 53(2):622-33.
    View in: PubMed
    Score: 0.001
  240. The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator. J Clin Invest. 1973 Oct; 52(10):2591-5.
    View in: PubMed
    Score: 0.001
  241. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol. 1993 Mar; 3(9):1563-9.
    View in: PubMed
    Score: 0.001
  242. Activation of factor XI in plasma is dependent on factor XII. Blood. 1993 Feb 01; 81(3):580-6.
    View in: PubMed
    Score: 0.001
  243. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med. 1972 Dec 01; 136(6):1378-93.
    View in: PubMed
    Score: 0.001
  244. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood. 1992 Oct 15; 80(8):1980-8.
    View in: PubMed
    Score: 0.001
  245. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med. 1972 Jan; 135(1):81-97.
    View in: PubMed
    Score: 0.001
  246. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 01; 133(4):696-712.
    View in: PubMed
    Score: 0.001
  247. The kallikrein-kinin system in inflammation. Adv Exp Med Biol. 1989; 247A:125-36.
    View in: PubMed
    Score: 0.001
  248. Expression of functional cell surface C1-inactivator by U937 cells. Clin Immunol Immunopathol. 1988 Dec; 49(3):463-77.
    View in: PubMed
    Score: 0.001
  249. Neutrophils and mast cells. Comparison of neutrophil-derived histamine-releasing activity with other histamine-releasing factors. J Immunol. 1988 Nov 15; 141(10):3575-83.
    View in: PubMed
    Score: 0.001
  250. The IgE-dependent release of a Hageman factor cleaving factor from human lung. Am J Pathol. 1986 Apr; 123(1):146-54.
    View in: PubMed
    Score: 0.001
  251. Quantitative assays of pharmacologic aerosols used in studying asthma. J Allergy Clin Immunol. 1985 Oct; 76(4):605-9.
    View in: PubMed
    Score: 0.001
  252. Synthesis of C1 inhibitor (C1-INA) by a human monocyte-like cell line, U937. J Immunol. 1985 Aug; 135(2):1313-9.
    View in: PubMed
    Score: 0.001
  253. Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin. J Clin Invest. 1985 Aug; 76(2):413-9.
    View in: PubMed
    Score: 0.001
  254. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. J Biol Chem. 1983 May 25; 258(10):6415-21.
    View in: PubMed
    Score: 0.001
  255. Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol. 1983 Feb; 26(2):249-57.
    View in: PubMed
    Score: 0.001
  256. Mechanisms for Hageman factor activation and role of HMW kininogen as a coagulation cofactor. Ann N Y Acad Sci. 1981; 370:253-60.
    View in: PubMed
    Score: 0.000
  257. Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. J Clin Invest. 1977 Jul; 60(1):7-17.
    View in: PubMed
    Score: 0.000
  258. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 1976 Nov 10; 251(21):6481-8.
    View in: PubMed
    Score: 0.000
  259. Hereditary vibratory angioedema: confirmation of histamine release in a type of physical hypersensitivity. J Allergy Clin Immunol. 1976 Jun; 57(6):605-8.
    View in: PubMed
    Score: 0.000
  260. Activation of surface-bound Hageman factor: pre-eminent role of high molecular weight kininogen and evidence for a new factor. Adv Exp Med Biol. 1976; 70(00):285-99.
    View in: PubMed
    Score: 0.000
  261. The use of isoelectric focusing to study components of the human plasma kinin-forming system. Ann N Y Acad Sci. 1973 Jun 15; 209:372-86.
    View in: PubMed
    Score: 0.000
  262. Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest. 1973 Jun; 52(6):1394-401.
    View in: PubMed
    Score: 0.000
  263. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. 1973 Jun; 52(6):1402-9.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.